<a href="https://www.fiercebiotech.com/biotech/kurma-closes-252m-vc-vehicle-coming-short-its-target-ahead-prior-fund" hreflang="en">Kurma closes €215M Europe-focused fund to spread across 20 biotechs</a>
Kurma Partners has successfully closed its fourth biotech venture capital fund, raising €215 million ($252 million) to invest in 16 to 20 European startups, despite falling short of its €250 million target. The fund aims to bridge the gap between scientific discovery and venture capital financing, with existing investments including companies focused on obesity and antibody-drug conjugates.
Kurma Partners' €215M Biofund IV underscores the growing focus on European biotech startups, despite falling short of its original target. This fund highlights significant opportunities for investing in early-stage biotechnology companies in Europe, particularly in healthtech sectors like obesity treatment and antibody-drug conjugate programs. For professionals tracking venture capital trends in biotech, this fund's deployment strategy and its backing by prominent investors like Bpifrance and CSL signal robust interest and potential in the European biotech landscape.